News Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

201120102009200820072003

2007 Archives

Dec 20, 2007
Companies Build on Existing Collaboration For Long Acting Blood Clotting Factors For Hemophilia

Nektar Therapeutics today announced a new agreement with subsidiaries of Baxter International Inc. to develop new PEGylated therapeutics for hemophilia. The program will begin preclinical...

More
Dec 11, 2007

Nektar Therapeutics announced today the promotion of John Nicholson to serve as Senior Vice President and Chief Financial Officer (CFO) of the company. Nicholson reports to Nektar's President and...

More
Nov 28, 2007

Nektar Therapeutics announced today that it is scheduled to present at the upcoming BMO Capital Markets Focus on Healthcare Conference in New York at the Millennium Broadway Hotel on Wednesday,...

More
Nov 14, 2007
Nektar Highlights Innovative New Product Development in the Areas of Oncology, Anti-Infectives, CNS and Pain Therapies

Nektar Therapeutics showcased its two industry-leading Pulmonary and PEGylation technology platforms and the company's innovative proprietary product pipeline at its R&D Day held today at The...

More
Nov 13, 2007

Nektar Therapeutics announced that it will host an R&D Day for investors and analysts at The Palace Hotel in New York, New York on Wednesday, November 14, 2007, beginning at 12:00 p.m. Eastern...

More
Nov 13, 2007

Pfizer and Nektar Therapeutics announced today that the two companies have resolved all outstanding contractual issues in connection with Exubera® and Nektar's innovative Next Generation Inhaled...

More
Nov 7, 2007

Nektar Therapeutics announced today the company's financial results for the third quarter that ended September 30, 2007. Revenue totaled $56.3 million in the third quarter of 2007 compared to...

More
Oct 31, 2007

Nektar Therapeutics will announce its financial results for the third quarter 2007 on Wednesday, November 7, 2007, after the close of U.S.-based financial markets. Howard Robin, president and...

More
Oct 25, 2007
Anti-Tumor Activity of NKTR-102 Associated With Increased and Sustained Exposure of Tumor Tissue to the Active Metabolite of Irinotecan

Nektar Therapeutics presented positive preclinical data today on its proprietary product candidate NKTR-102 (PEG-irinotecan) at the AACR-NCI-EORTC International Conference in San Francisco,...

More
Oct 18, 2007

Nektar Therapeutics issued a statement today in response to Pfizer's announcement this morning to exit Exubera, the inhaled insulin product to treat diabetes. "We first learned this morning of...

More
Oct 10, 2007

Nektar Therapeutics announced today that preclinical data for its proprietary product candidate NKTR-102 (PEG-irinotecan) will be presented at the upcoming AACR-NCI-EORTC International Conference...

More
Oct 2, 2007

Nektar Therapeutics announced that Howard W. Robin, president and CEO, will deliver the Nektar corporate presentation at the upcoming BIO InvestorForum at The Palace Hotel in San Francisco,...

More
Sep 27, 2007

Nektar Therapeutics announced positive new preclinical data today regarding its proprietary product candidate, NKTR-102 (PEG-irinotecan), which is under development for the treatment of solid...

More
Sep 26, 2007
NKTR-118 Currently in Phase 1 Clinical Development for the Treatment of Opioid Bowel Dysfunction

Nektar Therapeutics presented positive results this week from Phase 1 and preclinical studies of NKTR-118 (oral PEG-naloxol) at the American Academy of Pain Management (AAPM) meeting in Las Vegas,...

More
Sep 18, 2007

Nektar Therapeutics announced today that it has created two new Research Units to drive the company's research initiatives under Nektar's PEGylation and Pulmonary Business Unit Heads. The new...

More
Sep 13, 2007

Nektar Therapeutics announced that Howard W. Robin, president and CEO, will deliver the corporate presentation at the upcoming 2007 UBS Global Life Sciences Conference in New York at the Grand...

More
Sep 10, 2007
Results Demonstrate that NKTR-118 Shows Promise for the Treatment of Opioid Bowel Dysfunction

Nektar Therapeutics presented results today at the American College of Clinical Pharmacology conference in San Francisco, California from a Phase 1 trial of NKTR-118 (oral PEG-naloxol). NKTR-118...

More
Aug 29, 2007

Nektar Therapeutics announced today that Mr. Lutz Lingnau has been appointed to serve on its board of directors. Lingnau is a highly-respected pharmaceutical industry leader with over 35 years of...

More
Aug 23, 2007

Nektar Therapeutics today announced the appointment of Tim Harkness as Senior Vice President and CFO. Harkness reports to Nektar President and CEO Howard W. Robin, and will serve as an integral...

More
Aug 8, 2007

Nektar Therapeutics announced today the company's financial results for the second quarter that ended on June 30, 2007. Revenue totaled $65.9 million compared to $60.2 million in the second...

More
Aug 6, 2007
NKTR-061 (Inhaled Amikacin) Would Combine a Powerful Antibiotic With Innovative Pulmonary Drug Delivery System

Bayer HealthCare and Nektar Therapeutics announced today that the two companies have agreed to develop and commercialize NKTR-061 (inhaled amikacin). This potentially innovative therapy would...

More
Jul 26, 2007
NKTR-102 Currently in Phase 1 Clinical Trial to Evaluate Its Potential to Treat Solid Tumors

The first peer- reviewed presentations of preclinical data for Nektar Therapeutics' proprietary product, NKTR-102 (PEG-irinotecan) is scheduled to be presented at an upcoming scientific meeting...

More
Jul 26, 2007
Nektar's Proprietary NKTR-118 Being Studied For Its Potential to Treat Opioid-Induced Constipation

The first peer-reviewed preclinical and early Phase 1 clinical data for Nektar Therapeutics' proprietary product candidate, NKTR-118 (oral PEG-naloxol) are scheduled to be presented at two...

More
Jul 25, 2007

Nektar Therapeutics will announce its financial results for the second quarter 2007 on Wednesday, August 8, 2007, after the close of United States-based financial markets. Howard Robin, president...

More
 

print email rss
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide